Biomedical subjects

Yifat Linhart

Publications and source records attributed to Yifat Linhart.

3 recordsLinked to original sources

PubMed2005

Air transportation of corneal tissue: experience with local compared to transatlantic donor corneas.

PURPOSE: To compare the outcome of corneas obtained at the same hospital in which they were transplanted (group 1) to that of corneas obtained in the United States and grafted in Israel (group 2). METHODS: One hundred twenty-six patients undergoing corneal grafting in Israel during the years 1995 to 1998 were included in a retrospective, nonrandomized clinical trial. Group 1 included 31 procedures, and group 2 included 95. Data regarding preoperative condition, tissue characteristics, and postoperative outcome were collected from hospital charts. Statistically significant difference between groups was considered as P < 0.05. RESULTS: Follow-up time was 796 +/- 523 days for group 1 (mean +/- SD) and 815 +/- 510 days for group 2. Donor age and gender, recipient age and gender, graft size, and length of follow-up were similar. Time from preservation to transplantation was longer for group 2 (8.8 +/- 2.29 days) compared with in group 1 (3.13 +/- 2.38 days). Graft clarity was similar between groups 1 and 2 at 1 year (79% versus 71%) and at last follow-up visit (57% versus 62%). Visual acuity, intraocular pressure, and incidence of complications such as rejection (32% versus 38%), failure (35% versus 28%), secondary glaucoma (35% versus 43%), corneal ulcer (13% versus 6%), and regrafts (13% versus 7%) showed no difference between the groups. CONCLUSIONS: Air transport of corneal tissue, including loss of time due to travel and handling, did not compromise corneal transplantation success rate.

Aircraft↗

PubMed2005

Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel.

BACKGROUND: The varicella Oka/Merck vaccine has been shown to be very effective in clinical practice; however, several recent studies reported reduced effectiveness. The varicella Oka/GSK vaccine (Varilrix; GlaxoSmithKline Biologicals), which has been subjected to fewer effectiveness studies, was licensed in Israel for voluntary use in 2000. This study was planned to estimate the effectiveness of the varicella Oka/GSK vaccine among children 1-5 years of age. METHODS: Recent reports of varicella were retrieved from the Tel Aviv Health District. Two age-matched control subjects who attended the same day-care center and/or resided in the same neighborhood and had not contracted varicella in the past were recruited for each varicella case. The parents of case and control subjects were interviewed regarding the history of varicella vaccination and the severity of illness. RESULTS: A total of 151 case subjects (mean age, 2.9 +/-1.1 years) and 298 control subjects (mean age, 3.0 +/-1.1 years) were recruited. Vaccination rates for case and control subjects were 6.6% and 38.3%, respectively (P < 0.001). Disease among vaccinated children was significantly milder, as measured by several indices, including parental perception of the illness, presence of fever, time until the lesions dried and days of day care missed. Vaccine effectiveness against varicella of any severity with these figures was 88% (95% confidence interval, 77-94%), and effectiveness against moderate/severe illness was 100%. CONCLUSIONS: Our data demonstrate that the varicella Oka/GSK vaccine used in clinical practice is highly effective in prevention of varicella (especially moderate/severe disease) among children, including those attending day-care centers.

Age Distribution↗

PubMed2003

Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy.

The authors describe one patient with essential thrombocytosis and one with chronic hepatitis C infection who developed bilateral simultaneous anterior ischemic optic neuropathy within 3 months of starting treatment with interferon-alpha. One patient had several typical risk factors for conventional AION; the other did not. These cases are the fourth and fifth reported examples of this phenomenon. Interferon-alpha treatment may cause or aggravate the risk of developing anterior ischemic optic neuropathy. Vulnerable patients should be advised of this potential complication, assisted in reducing risk factors, and monitored for optic nerve and retinal vascular complications.

Adult↗